Editor's Correspondence |

Using Trade Names: Sometimes It Helps

Christopher Anton, MA, MEng; Anthony Richard Cox, BPharm, MRPharmS; Robin Esmond Ferner, MSc, MD, FRCP
Arch Intern Med. 2002;162(22):2636. doi:.
Text Size: A A A
Published online


We endorse the advice given by Schwab et al1 to prescribe by International Nonproprietary Name (INN) whenever possible.2 However, just as drugs given for the right reasons can have unintended adverse effects, so too can interventions designed to reduce one risk give rise to another. The use of brand names serves to distinguish products with the same active ingredient but different formulation or indication. Confusion over the formulation can have serious clinical consequences when calcium antagonists are prescribed. The British National Formulary states with regard to preparations of diltiazem, "Different versions of modified-release preparations may not have the same clinical effect. To avoid confusion between these different formulations of diltiazem, prescribers should specify the brand to be dispensed."3 A hospital consultant wrote to a family physician suggesting that he prescribe for his patient, an 82-year-old man, diltiazem LA (long acting), 300 mg. The family physician could not find this formulation listed and advised the patient to take 5 of his existing 60-mg diltiazem tablets in the morning; these were not long acting. The patient followed these instructions and 3 hours later collapsed and was admitted with complete heart block and a pulse rate of 38/min due to acute diltiazem poisoning. The hospital consultant intended the patient to receive Tildiem LA, 300 mg.4 A similar case has been reported with verapamil.5

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles